EVALUATION OF PATIENTS' RISK FACTORS FOR SURGICAL SITE INFECTIONS FOLLOWING SURGERY FOR GYNECOLOGIC CANCERS

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Alexandria

2 Obstetrics and gynecology faculty of medicine

3 Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria.

4 Department of Surgery, Faculty of Medicine, Alexandria University, Egypt

5 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Alexandria.

Abstract

Gynecologic cancers (GC) are among the most prevalent malignancies affecting women globally. Among the most common cancers, endometrial, ovarian, and cervical cancers account for almost one-third of all newly diagnosed cancers in women worldwide. Surgical site infection (SSI) is among the most prevalent health-care-associated infections (HAI). They follow between 10 and 35 percent of the gynecologic oncology surgeries performed worldwide. SSIs are defined as infections that happen within 30 days following surgery, according to the CDC and National Health Safety Network. Likewise, the US Centers for Disease Control and Prevention (CDC) have divided surgical site infections (SSIs) into three categories: deep, organ/space and superficial. The National Research Council of the USA developed a system for classifying incisions into clean, clean contaminated, and contaminated categories based on the degree of contamination of the incision. For patients with gynecologic oncology having laparotomy, the Enhanced Recovery after Surgery (ERAS) 2019 recommendations advocated the use of the surgical site infection reduction bundle (SSIRB). The adoption of these coordinated interventions has been strongly linked to SSI reduction.
The primary purposes of the surgical site infection reduction bundle are to sustain perioperative normoglycemia, preventing hypothermia, antimicrobial prophylaxis, and skin and bowel preparation.

Keywords